Literature DB >> 2574368

Clinical significance of Candida isolated from peritoneum in surgical patients.

T Calandra1, J Bille, R Schneider, F Mosimann, P Francioli.   

Abstract

Over a 2-year period, all surgical patients from whom Candida was isolated from intra-abdominal specimens were evaluated. All but 1 of the 49 evaluable patients had either a spontaneous perforation (57%) or a surgical opening of the gastrointestinal tract (41%). Candida caused infection in 19 patients (39%), of whom 7 had an intra-abdominal abscess and 12 peritonitis. In the other 30 patients (61%), there were no signs of infection and specific surgical or medical treatment was not required. Candida was more likely to cause infection when isolated in patients having surgery for acute pancreatitis than in those with either gastrointestinal perforations or other surgical conditions. The development of a clinical infection was significantly associated with a high initial or increasing amount of Candida in the semiquantitative culture. Surgery alone failed in 16 of 19 patients (84%), of whom 7 died and 9 recovered after combined antifungal and surgical treatment. The overall mortality and the mortality related to infections were significantly higher in the patients with intraabdominal candidal infections than in those without such infections.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574368     DOI: 10.1016/s0140-6736(89)92043-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  55 in total

Review 1.  Candida peritonitis: an update on the latest research and treatments.

Authors:  Herman Anthony Carneiro; Anastasios Mavrakis; Eleftherios Mylonakis
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

Review 2.  Candida albicans Pathogenesis: Fitting within the Host-Microbe Damage Response Framework.

Authors:  Mary Ann Jabra-Rizk; Eric F Kong; Christina Tsui; M Hong Nguyen; Cornelius J Clancy; Paul L Fidel; Mairi Noverr
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

3.  Candida spp. colonization significance in critically ill medical patients: a prospective study.

Authors:  Pierre Emmanuel Charles; Frédéric Dalle; Hervé Aube; Jean Marc Doise; Jean Pierre Quenot; Ludwig Serge Aho; Pascal Chavanet; Bernard Blettery
Journal:  Intensive Care Med       Date:  2005-02-12       Impact factor: 17.440

4.  Oral nystatin as antifungal prophylaxis in critically ill patients: an old SDD tool to be renewed?

Authors:  Philippe Eggimann; Michel Wolff; Jorge Garbino
Journal:  Intensive Care Med       Date:  2005-09-30       Impact factor: 17.440

Review 5.  [Antimicrobial and antimycotic therapy of intra-abdominal infections].

Authors:  P Kujath; M Hoffmann; A Rodloff
Journal:  Chirurg       Date:  2008-04       Impact factor: 0.955

6.  Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients.

Authors:  Laurence Senn; Philippe Eggimann; Riadh Ksontini; Andres Pascual; Nicolas Demartines; Jacques Bille; Thierry Calandra; Oscar Marchetti
Journal:  Intensive Care Med       Date:  2009-01-27       Impact factor: 17.440

7.  Fluconazole in Candida albicans sepsis during pregnancy: case report and review of the literature.

Authors:  E C Wiesinger; S Mayerhofer; C Wenisch; S Breyer; W Graninger
Journal:  Infection       Date:  1996 May-Jun       Impact factor: 3.553

Review 8.  Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later.

Authors:  Philippe Eggimann; Didier Pittet
Journal:  Intensive Care Med       Date:  2014-06-17       Impact factor: 17.440

Review 9.  Primary and secondary peritonitis: an update.

Authors:  M Laroche; G Harding
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

10.  Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections.

Authors:  Philippe Montravers; Annie Chalfine; Remy Gauzit; Alain Lepape; Jean Pierre Marmuse; Corinne Vouillot; Claude Martin
Journal:  Ann Surg       Date:  2004-03       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.